NASDAQ : CYTK
Cytokinetics, Incorporated — Key statistics
Healthcare · Biotechnology · United States
Last price 63.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 8.80B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 8.76B |
| Enterprise Value | 9.02B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 139.02M |
| Shares Outstanding | 139.02M |
| Shares Change (YoY) | +5.07% |
| Shares Change (QoQ) | +7.15% |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 117.03% |
| Float | 138.49M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 129.41 |
| Forward PS | 33.28 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 133.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.66 |
| Quick Ratio | 6.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.67 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -28.09% |
| Return on Invested Capital (ROIC) | -46.78% |
| Return on Capital Employed (ROCE) | -40.61% |
| Weighted Average Cost of Capital (WACC) | 6.56% |
| Revenue Per Employee | $100,550 |
| Profits Per Employee | -$1.33M |
| Employee Count | 673 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +1.61% |
| 50-Day Moving Average | 67.50 |
| 200-Day Moving Average | 70.08 |
| Relative Strength Index (RSI) | 45.99 |
| Average Volume (20 Days) | 1,685,320 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 18.63M |
| Short Previous Month | 19.33M |
| Short % of Shares Out | 13.40% |
| Short % of Float | 13.45% |
| Short Ratio (days to cover) | 8.18 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 67.67M |
| Gross Profit | -337.44M |
| Operating Income | -707.91M |
| Pretax Income | -894.00M |
| Net Income | -894.00M |
| EBITDA | -695.36M |
| EBIT | -707.91M |
| Loss Per Share | -$7.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.17B |
| Total Debt | 1.42B |
| Net Cash | -258.77M |
| Net Cash Per Share | -$1.86 |
| Equity (Book Value) | -173.49M |
| Book Value Per Share | -1.25 |
| Working Capital | 1.03B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -555.45M |
| Capital Expenditures | -25.26M |
| Depreciation & Amortization | 12.55M |
| Net Borrowing | 314.99M |
| Free Cash Flow | -580.72M |
| FCF Per Share | -$4.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,046.12% |
| Pretax Margin | -1,321.12% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.07% |
| Shareholder Yield | -5.07% |
| Earnings Yield | -11.40% |
| FCF Yield | -6.63% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $107.39 |
| Price Target Difference | 70.49% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 116.86% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.25 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |